第八因子抗体在获得的血友病A中表现出I型或II型动力学
Kirollos Kamel1, Sofia Sardo Infirri1, Anne Riddell1
1Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free Hospital, London, UK.
概括
获得的血友病A (AHA) 涉及对因子VIII (FVIII) 的自身抗体. 这项研究发现,AHA患者的FVIII自身抗体通常表现出I型或II型动力学,II型显示出更高的残留FVIII和更大的测试可变性.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 获得性血友病A (AHA) 是一种罕见的出血疾病,由针对第八因子 (FVIII) 的自身抗体引起.
- 在AHA中观察到明显的FVIII抑制剂动力学 (I型或II型),与严重的血友病A不同.
研究的目的:
- 在获得血友病A.患者中描述抑制剂动力学.
- 确定AHA中I型,II型和不确定的FVIII抑制剂动态的流行率.
主要方法:
- 在单一中心对成年AHA患者的抑制剂动力学的回顾性分析.
- 通过线性FVIII无活化 (≥97%) 定义的I型动力学和通过非线性动力学和不完全FVIII中和的II型动力学.
- 使用两种国际血液学标准化委员会 (ICSH) 方法计算了抑制剂标位.
主要成果:
- 在34名患者中,44.1%患有I型,47.1%患有II型,8.8%患有不确定的动力学.
- II型抑制剂与较高的残留FVIII:C (18.6 IU/dL对比2.9 IU/dL) 和较大的中位数位数差异 (15%对比5%) 相关.
- 与单独的非线性回归 (R2=38%) 相比,将动力学归类为I或II类型显著改善了回归模型的合适性 (R2=87%和85%).
结论:
- 在AHA中的FVIII自身抗体主要表现出I型或II型动力学.
- 具有II型动态的抑制剂在报告的标位中显示出更大的变化,这取决于所使用的测量方法.
- 了解抑制剂动力学对于准确诊断和管理获得的血友病A至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
Extrinsic and Intrinsic Pathways of Hemostasis
5.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.2K
Disorders of Hemostasis
694
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
694
Blood Typing
1.1K
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
1.1K
Clot Retraction and Fibrinolysis
3.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.7K
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K


